0
Your cart

Your cart is empty

Books > Medicine > General issues

Buy Now

ACE Inhibitors (Paperback, Softcover reprint of the original 1st ed. 2001) Loot Price: R1,450
Discovery Miles 14 500
ACE Inhibitors (Paperback, Softcover reprint of the original 1st ed. 2001): Pedro D'Orleans-Juste, G.E. Plante

ACE Inhibitors (Paperback, Softcover reprint of the original 1st ed. 2001)

Pedro D'Orleans-Juste, G.E. Plante

Series: Milestones in Drug Therapy

 (sign in to rate)
Loot Price R1,450 Discovery Miles 14 500 | Repayment Terms: R136 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions.

General

Imprint: Springer Basel
Country of origin: Switzerland
Series: Milestones in Drug Therapy
Release date: September 2012
First published: 2001
Editors: Pedro D'Orleans-Juste • G.E. Plante
Dimensions: 244 x 170 x 10mm (L x W x T)
Format: Paperback
Pages: 187
Edition: Softcover reprint of the original 1st ed. 2001
ISBN-13: 978-3-03-487581-3
Categories: Books > Medicine > General issues > General
LSN: 3-03-487581-9
Barcode: 9783034875813

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners